Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $32,003 | $50,200 |
| General and administrative | 14,089 | 14,991 |
| Total operating expenses | 46,092 | 65,191 |
| Loss from operations | (46,092) | (65,191) |
| Other income (expenses), net: | ||
| Interest and other income, net | 3,573 | 5,516 |
| Interest expense | (300) | (150) |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's G&A?
- Allogene Therapeutics (ALLO) reported G&A of $14.09M in Q1 2026.
- How has Allogene Therapeutics's G&A changed year-over-year?
- Allogene Therapeutics's G&A decreased by 6.0% year-over-year, from $14.99M to $14.09M.
- What is the long-term trend for Allogene Therapeutics's G&A?
- Over 4 years (2021 to 2025), Allogene Therapeutics's G&A has grown at a -6.4% compound annual growth rate (CAGR), from $74.11M to $56.78M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Allogene Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude